Answers are grounded in this paper and cite their sources.
A biotin-modified polyethylene glycol–paclitaxel nanocarrier was developed for the co-delivery of paclitaxel and oxaliplatin in colorectal cancer therapy. The biotin–PEG–PTX copolymer was synthesized and characterized by FTIR spectroscopy, and paclitaxel nanoparticles and oxaliplatin-loaded nanoparticles were prepared through self-assembly. Their physicochemical properties, stability, morphology, and drug-release behavior were evaluated using DLS, TEM, and in vitro release assays. OXA@PTX nanoparticles inhibited HCT-116 cell growth, showed combination-associated cytotoxicity and time-dependent nanoparticle-associated fluorescence, and produced lower macrophage-associated fluorescence than free FITC under the tested conditions. In tumor-bearing mice, the formulation showed qualitatively greater tumor-associated fluorescence, reduced Ki-67 expression, and increased TUNEL staining, with no obvious histopathological abnormalities in major organs. The nanocarrier also exhibited sustained, pH-dependent drug release, supporting its potential as a biotin-functionalized platform for paclitaxel and oxaliplatin co-delivery in colorectal cancer therapy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: